{"schema_version":"secwatch.filing_event.v1","accession":"0001559053-22-000003","form_type":"8-K","ticker":"PRTA","cik":"0001559053","company_name":"PROTHENA CORP PUBLIC LTD CO","filed_at":"2022-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.979197+00:00","generated_at":"2026-06-27T07:03:03.183869+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Prothena reports FY2021 net income of $67M; cash $580M; pipeline advances with SPA and partnerships","bullets":["FY2021 revenue $200.6M (vs $0.9M in 2020); net income $67.0M vs net loss $111.1M in 2020.","Cash and restricted cash $580.4M at Dec 31, 2021, no debt; raised $175M in equity in 2021.","Received $80M BMS option for PRX005, $60M Roche milestone for prasinezumab, $60M upfront from Novo Nordisk for ATTR.","Reached SPA agreement with FDA for confirmatory Phase 3 AFFIRM-AL study of birtamimab in AL amyloidosis; Phase 1 of PRX005 initiated.","2022 guidance: net cash used $120-132M; expected net loss $154-170M; ending cash ~$454M."],"urls":{"canonical":"https://secwatch.observer/filing/0001559053-22-000003","json":"https://secwatch.observer/filing/0001559053-22-000003.json","markdown":"https://secwatch.observer/filing/0001559053-22-000003.md","text":"https://secwatch.observer/filing/0001559053-22-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559053/000155905322000003/0001559053-22-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559053/000155905322000003/prta-20220217.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T07:03:03.183869+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}